Author

Feng Hu

East China University of Science and TechnologyPrimary ORCID profile (0000-0002-0865-0206 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Feng HuiD3 papers · Agricultural Genomics Institute at Shenzhen

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Aaliyah Washington· 1 shared Alberto VidesiD· 1 shared Alexander I. SpiraiD· 1 shared Andrea MorenoiD· 1 shared Andrew G. HortiiD· 1 shared Antonello BonciiD· 1 shared Antonio Cuevas-NavarroiD· 1 shared Aparna HegdeiD· 1 shared

Activity by Year

2017-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaliyah Washington

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer

Huan He, Manzhan Zhang, Xiaoxiao Yang, Shuai He, Xiayu Shi, Feng Hu, Chang Liu, Xingsen Zhang, Na Chen, Xiaoqian Zhu, Leihao Zhang, Tianyu Ye, Rong Zhang, Yanru Yang, Rui Wang, , Shiliang Li

The paper develops ConMeter, a metabolite prediction model, and uses it to design an orally bioavailable RSK4 inhibitor with improved bioavailability and anti-tumor efficacy against esophageal cancer.

bioRxiv · Jun 2, 2025 · PreprintCancer Biology

Mechanisms of resistance to active state selective tri-complex RAS inhibitors

Ben Sang, Ling Feng Ye, Feng Hu, Yasin Pourfarjam, Antonio Cuevas-Navarro, Shijie Fan, Zheng Qing Fu, Aaliyah Washington, Diego J. Rodriguez, Alberto Vides, Sumit Kar, Ethan Ahler, Kevin K. Lin, Aparna Hegde, Jacqueline A.M. Smith, , Piro Lito

This study identifies mechanisms of resistance to tri-complex RAS inhibitors in patients with RAS-driven cancers, showing that resistance alterations disrupt the RAS:drug:CYPA tri-complex formation.

bioRxiv · Apr 24, 2025 · PreprintCancer Biology

Chemogenetic ligands for translational neurotheranostics

Jordi Bonaventura, Mark A. G. Eldridge, Feng Hu, Juan L. Gomez, Marta Sánchez‐Soto, Ara M. Abramyan, Sherry Lam, Matthew A. Boehm, Christina M. Ruiz, Mitchell R. Farrell, Andrea Moreno, Islam Mustafa Galal Faress, Niels Andersen, John Y. Lin, Ruin Moaddel, , Michael Michaelides

The paper develops new DREADD agonists and a PET radiotracer for improved neuronal activity manipulation and noninvasive projection mapping in neurotheranostics.

bioRxiv · Dec 7, 2018 · PreprintNeuroscience

Identification of disease resistance genes from a Chinese wild grapevine (Vitis davidii) by analysing grape transcriptomes and transgenic Arabidopsis

Ying Zhang, Jia‐Long Yao, Feng Hu, Jianfu Jiang, Xiucai Fan, Haisheng Sun, Yunfei Jia, Yanyan Zhu, Ran Wang, Chonghuai Liu

The paper identifies disease resistance genes in Chinese wild grapevine by comparing transcriptomes and validates one gene's role in enhancing resistance in Arabidopsis.

bioRxiv · Jul 28, 2017 · PreprintMolecular Biology